DTC Ad Risk Disclosures Could Be Limited To ‘Serious And Actionable’
Executive Summary
Despite PhRMA’s concerns, FDA is proceeding with a study using modified versions of existing TV ads, but agency will revise study questions to focus on value of the ‘major statement’ and not other aspects of ads.
You may also be interested in...
DTC Study Shows Limited Risk Statement Works, But Will Pharma Ad Practices Change?
Viewers retain more risks and benefits in DTC ads showing only limited risk information, but experts predict it may not result in substantial change right away.
Permanent Vaccine Facility Should Be On Standby For Future Pandemics, Moncef Slaoui Says
Operation Warp Speed confirmed the necessity of having a facility on hand to develop and manufacture a vaccine for the next crisis, the outgoing advisor says.
FDA’s COVID-19 Pandemic Plan Calls For Ongoing Clinical Trial Innovation
Broader use of adaptive trial designs and master protocols, checklist-based application review, and enhancement of real-world monitoring of products are among the recommendations of US FDA's COVID-19 Pandemic Recovery and Preparedness Plan (PREPP) report, an effort months in making based on interviews with agency management, staff, and outside stakeholders.
Need a specific report? 1000+ reports available
Buy Reports
Register for our free email digests: